An NCI-designated Comprehensive Cancer Center
Alexey Danilov Bio

Alexey Danilov, M.D., Ph.D.

Hematologist - Oncologist
Clinical Expertise
  • Hematology - Oncology
  • Hematology & Hematopoietic Cell Transplantation
  • Lymphoma
  • Leukemia
Research Focus
  • Lymphoma Malignancies
Associate Director, Toni Stephenson Lymphoma Center; Professor, Department of Hematology & Hematopoietic Cell Transplantation

Clinical Teams

Research Teams

  • Lymphoma Research
“In oncology today, we are given great opportunities to make a lot of positive impact on the lives of our patients.”
Alexey Danilov, M.D., Ph.D., chose oncology as a career because of its breadth and potential. Oncology, he says, “touches all areas of general medicine” and is a most exciting field because of the many new treatments now emerging.
A board-certified clinician and talented researcher, Dr. Danilov focuses on blood cancers, including chronic lymphocytic leukemia and many forms of lymphoma. He is a Leukemia & Lymphoma Society Scholar in Clinical Research.
A native of Russia, Dr. Danilov earned his medical degree and Ph.D. at Yaroslavl State Medical Academy. He continued his training with a residency at Brown University in Providence, Rhode Island, and a fellowship at Tufts Medical Center in Boston.
An ideal fit for City of Hope, Dr. Danilov’s lab concentrates on “bench to bedside” medicine, where preclinical findings lead to early phase clinical trials, ultimately translating into real treatments for real patients.


City of Hope Comprehensive Cancer Center, 1500 East Duarte Road

Duarte, CA 91010

1. Best SR, Hashiguchi T, Kittai A, Bruss N, Paiva C, Okada C, Liu T, Berger A, and Danilov AV2019. Targeting ubiquitin-activating enzyme induces ER stress-mediated apoptosis in B-cell lymphoma cells. Blood Advances. In press.

2. Best SR, Liu T, Bruss N, Kittai A, Berger A, and Danilov AV2019. Pharmacologic inhibition of the ubiquitin-activating enzyme induces ER stress and apoptosis in chronic lymphocytic leukemia and ibrutinib-resistant mantle cell lymphoma cells. Leukemia & Lymphoma (invited manuscript). In press.

3. Gordon M, Churnetski M, Alqahtani H, Rivera X, Kittai A, Amrock SM, James S, Hoff S, Manda S, Spurgeon SE, Choi M, Cohen JB, Persky D, Danilov AV2018. Comorbidities predict inferior outcomes in chronic lymphocytic leukemia treated with ibrutinib. Cancer. 124(15): 3192-3200.

4. Tyner JW, Tognon CE, Bottomly D, Wilmot B, Kurtz S, Savage S, Long N, Reister-Shulz A, Traer E, Abel M, ….., Danilov AV, ….., Druker BD. 2018. Functional genomic landscape of acute myeloid leukemia. Nature. doi: 10.1038/s41586-018-0623-z

5. Calzada O, Switchenko JM, Maly JJ, Blum KA, Grover N, Mathews S, Park SI, Gordon M, Danilov A, Epperla N, Fenske TS, Hamadani M, Flowers CR, Cohen JB. 2018. Deferred treatment is a safe and viable option for select patients with mantle cell lymphoma. Leukemia & Lymphoma. Jun 18: 1-9.

6. Greenwell IB, Staton AD, Lee MJ, Switchenko JM, Saxe DF, Maly JJ, Blum KA, Grover NS, Mathews SP, Gordon MJ, Danilov AV, Epperla N, Fenske TS, Hamadani M, Park SI, Flowers CR, Cohen JB. 2018. Complex karyotype in patients with mantle cell lymphoma predicts inferior survival and poor response to intensive induction therapy. Cancer. 124 (11): 2306-2315.

7. Edwards D, Sweeney T, Ho H, Eide CA, Rofelty A, Agarwal A, Liu SQ, Danilov AV, Lee P, Chantry D, McWeeney SK, Druker BJ, Tyner JW, Spurgeon SS and Loriaux MM. 2018. Targeting of colony-stimulating factor 1 receptor (CSF1R) in the CLL microenvironment yields antineoplastic activity in primary patient samples. Oncotarget. 15; 9(37): 24576-24589.

8. Paiva C, Rowland TA, Sreekantham B, Godbersen C, Best SR, Kaur P, Loriaux MM, Spurgeon SE, Danilova OV and Danilov AV2017. SYK inhibition thwarts the BAFF - B-cell receptor crosstalk and thereby antagonizes Mcl-1 in CLL. Haematologica. 102 (11): 1890-1900.

9. Gay ND, Kozin E, Okada CY, Danilov AV, and Spurgeon SE. 2017. Obinutuzumab monotherapy in previously untreated chronic lymphocytic leukemia. Leukemia & Lymphoma. Dec 18: 1-3.

10. Paiva C, Godbersen JC, Rowland T, Danes C, Berger A, and Danilov AV2017. Pevonedistat, a Nedd8-activating enzyme inhibitor, sensitizes neoplastic B-cells to death receptor-mediated apoptosis. Oncotarget. 8(13):21128-21139.

11. Skopeja S, Jones JD, Hamilton J, Danilov AV and Rigby WFC. 2017. Differential effector function of obinutuzumab (GA101) and rituximab on normal and CLL B cells. Journal of Immunology. 199 (4): 1275-1282.

12. Danilov AV, Li H, Press OW, Shapira I, Swinnen LJ, Noy A, Reid E, Smith SM and Friedberg JW. 2017. Feasibility of interim positron emission tomography (PET)-adapted therapy in HIV-positive patients with advanced Hodgkin lymphoma (HL): a sub-analysis of SWOG S0816 phase 2 trial. Leukemia & Lymphoma. 58(2): 461-465.

13. Agarwal A, Salem AH, Danilov AV, Hu B, Puvvada S, Gutierrez M, Chien D, Lewis LD and Wong SL. 2017. Effect of ketoconazole, a strong CYP3A inhibitor, on the pharmacokinetics of venetoclax, a Bcl-2 inhibitor, in patients with non-Hodgkin lymphoma. British Journal of Clinical Pharmacology. 83(4): 846-854.

14. Danilov AV, Lewis LD, Lansigan F, Jones SY, Roudaia L, Highhouse B, Beaulieu BB and Brown JR. 2017. A Phase I dose-ranging study of Bendamustine and Rituximab (BR) in chronic lymphocytic leukemia (CLL) patients with comorbidities. British Journal of Haematology. 178 (5): 820-823.

In The News
An Expert's Voice
Alexey Danilov Bio

Data-driven scientist to help lead blood cancer effort